Abstract:1862 Objectives: To prepare 99mTc-IT-rituximab, a novel sentinel lymphoscintigraphy agent, and evaluate its ability in detecting the sentinel lymph node. Methods: Rituximab was radiolabeled with 99mTc via 2-iminothiolane (2-IT). The resulting 99mTc-IT-Rituximab were analysed for number of free sulfhydryl groups. The integrity of IT-rituximab was evaluated by SDS-PAGE, ELISA, which could evaluated the optimal modifying conditions. The immunological biology of 99mTc-IT-rituximab was evaluated by flow-cytometric analysis (FCA). Comparing the radiocolloid, 99mTc-IT-Rituximab was evaluated with biological distribution results, and image of sentinel lymph node (SLN) was obtained at 30min-24h postinjection with 99mTc-IT-rituximab in mice. The influenced factors on the imaging by the injecting dosage and volume were also observed in mice. Results: Optimal conditions for modifying Rituximab involved a 10:1 molar ratio of 2-IT : protein in 4°C, the number of apparent thiol produced were 2.1 per IT-Rituximab. 99mTc-IT-rituximabwas stable for 24 h at 37°C in human serum. 99mTc-IT-rituximab was proved to have the similar immunological character with rituximab by SDS-PAGE, ELISA and FCA. Its binding rate of B lymphoma cell line Raji cell is 69.4%. After subcutaneous injection into the foot pads of mice, 99mTc-IT-rituximab showed high accumulationn the knee. The mean %ID of the popliteal lymph node at 1, 4, 8, and 24 h was (2.33±0.13)%, (2.72±0.12)%, (3.71±0.28)%, and (4.49±0.43)%, respectively. The mean %ID of NSLN was less than 0.2% at each time point. With increasing the injected dose or volume the %ID of SLN would decrease, while the %ID of NSLN would increase gradually. 99mTc-IT-rituximab exhibited faster injection site clearance than did 99mTc-SC and 99mTc-DX, %ID of the rear paws was (22.14±2.08)% at 24 h after administration. In mice, the results of dynamic SLN mapping show that SLN could be seen within a wide range from 30 min to 24 h postinjection. The higher order nodes had not been seen all the time. 99mTc-IT-rituximab was mainly excreted by kidney, other tissues exhibited less than 1 percent of the injected dose at all time points. For radiocolloid, the higher echelon node extraction was significantly higher. The 99mTc-SC and 99mTc-DX %ID of the second-order node was (4.93±0.37) % and (8.54±0.78) % at 2 h. The uptake of second echelon for 99mTc-HSA was also higher than 99mTc-IT-rituximab. Conclusions: 99mTc-IT-Rituximab, as a tracer to mapping SLN, could predict the status of SLNs reliably.

The primary clinical study on radioimmunoscintigraphy with ~(131)Ⅰ-rituximab for B cell lymphoma

The experimental study on biodistribution and radioimmunoimaging of 131I labeled anti-lymphoma Fab antibody in nude mice bearing human B cell lymphoma

Clinical Evaluation of 99Mtc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients.

Clinical Evaluation of 99 mTc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients

Development and animal study of sentinel lymph node imaging with a novel radiotracer

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

Sentinel Lymph Node Imaging with a Novel Radiotracer: Preparation of 99Tcm-It-rituximab and Experimental Study

The results of sentinel lymph node imaging and biopsy with a novel lymphoscintigraphy agent 99 Tc m -Rituximab in 247 breast cancer patients

Technetium-99m-Labeled Rituximab For Use As A Specific Tracer Of Sentinel Lymph Node Biopsy: A Translational Research Study

The Efficacy of 99Mtc-Rituximab As a Tracer for Sentinel Lymph Node Biopsy in Cutaneous Melanoma Patients

99Mtc-It-rituximab: an Effective Radiotracer for Identifying Sentinel Lymph Nodes in Breast Cancer

Evaluating 64Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18F-fluorodeoxyglucose PET/computed tomography

The results of sentinel lymph node imaging and biopsy with a novel lymphoscintigraphy agent 99Tcm-Rituximab in 467 breast cancer patients

Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient]

The preparation and localization study of a novel sentinel lymphoscintigraphy agent 99Tcm-IT-Rituximab

Sentinel Lymph Node Biopsy with a Novel Sentinel Lymphoscintigraphy Agent 99Mtc-Rituximab for Breast Cancer

Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma

99Mtc-Rituximab Sentinel Lymph Node Mapping and Biopsy, the Effective Technique Avoids Axillary Dissection and Predicts Prognosis in 533 Cutaneous Melanoma.

[Preliminary Study of New Imaging Agent, 99Mtc-Rituximab, for Sentinel Lymph Node Biopsy of Primary Breast Cancer].

Application of sentinel lymph node biopsy assisted by 99Tcm-IT-Rituximab in cutaneous malignant melanoma of limbs

Experimental Study of Biological Property and Safety Limitation of Sentinel Lymph Node Imaging Agent 99Tcm-Rituximab